Market Outlook

By 2032, the U.S. Single-Use Point-of-Care Testing Devices Market is projected to reach approximately USD 29.84 billion, expanding at a CAGR of 8.73% during the forecast period 2027–2032. The market stood at USD 18.06 billion in 2026, following historical values of USD 14.18 billion in 2023, USD 15.35 billion in 2024, and USD 16.64 billion in 2025. Values in this report are expressed in USD billions.

The U.S. single-use point-of-care testing devices industry operates at the vital nexus of decentralized clinical decision-making, hospital emergency triage optimization, ambulatory care expansion, microfluidic consumable innovation, and CLIA-waived diagnostic protocols. Demand is propelled by the structural imperative to compress therapeutic turnaround times, mitigate inpatient lengths of stay, address systemic nursing and laboratory technologist labor shortages, and fulfill stringent value-based clinical quality metrics mandated by the Centers for Medicare and Medicaid Services. Across emergency departments, intensive care suites, urgent care chains, and ambulatory surgical centers, single-use testing devices have transitioned from supplementary screening tools into primary diagnostic instruments that drive immediate clinical action.

Clinical urgency across acute care environments mandates that biochemical and molecular parameters be delivered within minutes rather than the multi-hour processing cycles characteristic of centralized core laboratories. Approximately 137 million patients present annually to emergency departments across the United States, where overcrowding and boarding times have escalated operational risks. Implementing single-use, rapid-turnaround cartridges for high-sensitivity cardiac troponin, blood gases, lactate, and creatinine reduces patient discharge times by an average of 42 minutes, directly improving emergency department throughput and mitigating ambulance diversion rates.

Concurrently, the rapid decentralization of healthcare delivery toward urgent care clinics, retail health environments, and physician office laboratories has permanently altered the procurement geography for medical diagnostic hardware. More than 14,000 urgent care centers and 11,000 retail health clinics now manage acute episodic illnesses throughout North America, requiring self-contained, disposable testing platforms that eliminate reagent preparation, liquid handling, external calibration, and hazardous bio-waste containment protocols. These care settings require single-use microfluidic and lateral flow cartridges capable of processing non-invasive capillary whole blood, nasal swabs, or urine specimens with zero risk of instrument-borne cross-contamination.

The regulatory environment governed by the U.S. Food and Drug Administration and the Clinical Laboratory Improvement Amendments has created a highly favorable pathway for single-use POCT platforms. Manufacturers are engineering disposable test cartridges with integrated procedural controls, internal sample processing, and foolproof microfluidic fluidics that achieve CLIA-waived categorization. CLIA waiver classifications allow non-laboratory personnel, such as registered nurses, medical assistants, and emergency medical technicians, to execute high-complexity diagnostic assays at bedside without violating federal clinical laboratory operational standards.

The historical period from 2023 through 2025 was marked by post-pandemic stabilization and the strategic redeployment of decentralized testing capital. Healthcare facilities rationalized their diagnostic inventories, transitioning away from standalone single-target pandemic platforms toward versatile, multi-pathogen multiplex syndromic single-use cartridges. Hospital procurement committees conducted systematic clinical workflow audits, integrating disposable test cartridges into electronic health record networks via wireless point-of-care connectivity hubs. From 2027 onward, market expansion will be anchored by next-generation single-use molecular cartridges, high-sensitivity disposable cardiac biosensors, microfluidic blood gas cards, and single-use digital immunoassays deployed across acute, ambulatory, and home-care settings.

 

Introduction

According to the U.S. Single-Use Point-of-Care Testing Devices Market Report, single-use point-of-care diagnostics represent the most clinically critical and commercially resilient segment of the American in vitro diagnostic ecosystem. The clinical care pathway of a modern patient increasingly depends on instantaneous analytical feedback. A patient presenting to a community hospital emergency department with acute chest pain requires an immediate single-use troponin assay to rule out myocardial infarction; an outpatient presenting to an urgent care clinic with fever and respiratory distress undergoes a single-use multiplex RT-PCR or isothermal swab test to differentiate between Influenza A, Influenza B, RSV, and SARS-CoV-2; while a septic inpatient in an intensive care unit requires serial microfluidic disposable blood gas and lactate measurements to guide hemodynamic fluid resuscitation.

This clinical paradigm establishes a commercially lucrative model defined by recurring, high-margin, single-use consumable utilization. While central laboratory clinical chemistry analyzers involve capital equipment investments with multi-year depreciation schedules, single-use point-of-care testing functions within an operational expenditure framework where hospitals and clinics consume hundreds of millions of pre-packaged test strips, lateral flow cassettes, and microfluidic cartridges annually. The unit economics of these single-use consumables reflect strong gross margin profiles for manufacturers, protected by proprietary cartridge architectures and closed-system instrument-reagent locking mechanisms that prevent third-party consumable substitution.

Reimbursement mechanisms governed by the Medicare Clinical Laboratory Fee Schedule and commercial third-party payers have reinforced the adoption of single-use rapid testing. Specific Current Procedural Terminology codes for rapid antigen detection, enzymatic electrochemical monitoring, and single-use nucleic acid amplification provide healthcare organizations with immediate, fee-for-service reimbursement margins. Furthermore, under value-based payment models and the Hospital Readmissions Reduction Program, hospitals utilize single-use point-of-care devices to expedite therapeutic decisions, reduce hospital-acquired infection risks, and avoid Medicare reimbursement penalties associated with preventable 30-day readmissions.

The operational reality of American acute care institutions differs markedly from theoretical diagnostic models. U.S. hospitals operate under acute shortages of certified medical laboratory scientists, with clinical laboratory vacancy rates averaging 13.5% across urban and rural hospital networks. This staffing deficit prevents central laboratories from meeting rapid turnaround time benchmarks for STAT testing. Single-use diagnostic devices circumvent this bottleneck by placing analytical capabilities directly into the hands of bedside nursing staff. Single-use testing cartridges require no complex pipetting, manual reagent reconstitution, or optical alignment, minimizing human technical error and streamlining diagnostic execution.

The single-use point-of-care testing footprint is extending aggressively into home health and remote patient monitoring networks. The rising prevalence of chronic cardiometabolic disorders, including Type 1 and Type 2 diabetes, chronic kidney disease, and congestive heart failure, drives steady demand for single-use electrochemical test strips, disposable capillary collection micro-cartridges, and single-use urinalysis test formats. Concurrently, mobile paramedic response units and hospital-at-home healthcare teams utilize rugged, single-use diagnostic cartridges to deliver clinical laboratory-quality analysis within residential living spaces, avoiding expensive emergency department transports and inpatient admissions.

From 2027 through 2032, device vendors will compete on microfluidic cartridge architecture, analytical limit of detection, multi-analyte multiplexing capability, ambient temperature shelf-stability, and enterprise informatics connectivity. Leading medtech manufacturers are investing heavily in roll-to-roll microfluidic manufacturing, lyophilized bead reagent stabilization, and embedded optical calibration sensors. The diagnostic organizations that dominate the market will be those that engineer robust, room-temperature-stable single-use cartridges that deliver laboratory-reference diagnostic sensitivity within ten minutes, accompanied by seamless, automated data transfer into hospital electronic medical record networks.

 

Key Market Drivers: What’s Fueling the U.S. Single-Use Point-of-Care Testing Devices Market Boom?

The foremost growth driver is the clinical demand for radical turnaround time compression in acute emergency, trauma, and critical care settings. In life-threatening emergencies such as acute coronary syndromes, acute ischemic stroke, hemorrhagic shock, and septic shock, clinical outcomes deteriorate rapidly with every thirty-minute delay in targeted intervention. Central core laboratory transport, accessioning, centrifugation, and queue times frequently delay critical diagnostic results beyond the therapeutic window. Single-use point-of-care test devices eliminate specimen transit and pre-analytical sample preparation delays by accepting uncentrifuged whole blood, saliva, or nasal swabs directly at the bedside, delivering actionable quantitative results within three to fifteen minutes. This rapid feedback allows emergency physicians to administer thrombolytics, initiate targeted antibiotic protocols, or adjust vasoactive infusions with confidence.

A second driver is the structural deficit of certified medical laboratory professionals across the United States. Vacancy rates for clinical laboratory technicians and technologists have reached unprecedented levels, exacerbated by widespread retirements and insufficient graduates from accredited medical laboratory science programs. Hospital administrators can no longer rely exclusively on centralized laboratory workforces to execute round-the-clock STAT diagnostic menus. Single-use point-of-care testing devices, engineered with fool-proof microfluidics, self-calibrating electrochemical sensors, and factory-embedded barcode calibration curves, permit non-laboratorians, including bedside nurses, respiratory therapists, and emergency medical technicians, to perform critical diagnostic assays within regulatory compliance. This operational shift preserves skilled laboratory labor for complex, batch-processed analytical workflows.

A third driver is the rapid expansion of alternative outpatient clinical settings, notably urgent care centers, retail health clinics, and ambulatory surgery centers. Consumer preference for accessible, convenient healthcare has led to an explosion of urgent care centers across suburban and urban corridors. These facilities lack the physical footprint, biological containment infrastructure, and capital budgets required to support central core laboratory analyzers. Instead, they rely on single-use lateral flow strips, disposable molecular cartridges, and handheld electrochemical meters to diagnose streptococcal pharyngitis, respiratory viral infections, urinary tract infections, and sexually transmitted infections during a single patient encounter, preserving clinical profitability and patient satisfaction.

A fourth driver is the strategic evolution of the regulatory framework governed by the FDA Center for Devices and Radiological Health, specifically regarding CLIA Waiver by Application pathways. The FDA has actively supported the transition of complex diagnostic tests toward CLIA-waived status when manufacturers demonstrate that assays incorporate robust failure-detection mechanisms and yield negligible rates of user-induced error. The availability of CLIA waivers for rapid single-use molecular tests, multiplex respiratory cassettes, and high-sensitivity immunoassay cartridges has democratized access to advanced diagnostic testing, allowing tens of thousands of outpatient practices, workplace clinics, and skilled nursing facilities to procure and operate these platforms without complex regulatory hurdles.

A fifth driver is the clinical mandate to eliminate cross-contamination and nosocomial pathogen transmission within hospital environments. Reusable medical diagnostic equipment, particularly instruments that require liquid cleaning, reusable sample probes, or internal fluidic tubing, represents a documented vector for the transmission of multi-drug-resistant organisms, including Methicillin-resistant Staphylococcus aureus, Vancomycin-resistant Enterococci, and Clostridioides difficile. Single-use point-of-care testing devices encapsulate the entire biological specimen, chemical reagents, and reaction chambers within a hermetically sealed disposable cartridge. Following assay execution, the entire cartridge is discarded directly into biohazard waste, preventing patient-to-patient and patient-to-operator cross-contamination and aligning with the infection control standards of the Joint Commission.

A sixth driver is the rising clinical prevalence and economic burden of chronic cardiometabolic diseases across aging American demographics. Over 38 million Americans live with diabetes, while more than 120 million adults suffer from hypertension, cardiovascular disease, or chronic kidney damage. Managing these multi-system diseases requires frequent, decentralized physiological monitoring. The single-use consumable footprint, spanning glucose biosensor strips, capillary blood ketone strips, microalbumin test strips, and point-of-care lipid and liver function panels, creates stable, volume-driven recurring revenue streams. The continuous shift toward preventative disease management and outpatient chronic disease monitoring guarantees consistent consumable replacement cycles across commercial and Medicare populations.

Finally, advancements in ambient-temperature reagent stabilization and microfluidic manufacturing economies have removed historical logistics bottlenecks. Historically, molecular and enzymatic point-of-care testing required continuous cold-chain storage and refrigeration, limiting utility in non-traditional healthcare environments. Modern single-use cartridges leverage advanced lyophilization, ambient-dry reagent casting, and micro-encapsulated liquid buffers that maintain full analytical efficacy at room temperature for twelve to twenty-four months. Furthermore, high-speed automated roll-to-roll embossing and ultrasonic welding manufacturing techniques have lowered single-use cartridge production costs, allowing medtech vendors to offer competitive per-test price points to hospital procurement networks.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation within the U.S. single-use point-of-care testing devices sector has advanced past simple colorimetric test paper strips toward sophisticated, self-contained microfluidic laboratories-on-a-chip. Device manufacturers are integrating micro-scale fluid mechanics, solid-state electrochemical sensors, embedded optical waveguides, and room-temperature enzymatic stabilization into disposable plastic cartridges smaller than a credit card.

In microfluidic cartridge architecture, developers have replaced passive capillary flow with precise, on-cartridge pneumatic and acoustic fluid manipulation. Single-use cartridges now incorporate integrated elastomeric micro-pumps, micro-valves, and capillary stop-junctions that meter precise nanoliter volumes of whole blood, separate plasma from cellular fractions without centrifugation, and sequentially mix sample volumes with lyophilized reagents. This automated on-chip sample processing eliminates manual specimen manipulation, ensuring that raw whole blood samples yield analytical precision comparable to central laboratory automated chemistry analyzers.

Single-use molecular diagnostics have undergone a technological revolution through the integration of rapid isothermal nucleic acid amplification technologies, such as Loop-Mediated Isothermal Amplification, Recombinase Polymerase Amplification, and ultra-rapid microfluidic RT-PCR. These technologies eliminate bulky, power-hungry thermal cyclers, allowing single-use disposable cartridges to execute cell lysis, nucleic acid extraction, enzymatic amplification, and fluorescent detection within a compact form factor. Single-use molecular cartridges now deliver definitive viral and bacterial identification in twelve to twenty minutes, offering true polymerase chain reaction-grade sensitivity and specificity directly at outpatient triage desks.

Electrochemical biosensor engineering has achieved marked improvements in analytical sensitivity through the deployment of nanostructured electrode surfaces, carbon nanotube arrays, and graphene field-effect transistors. Modern single-use electrochemical test strips do not merely detect glucose via basic glucose oxidase pathways; they measure subtle electron-transfer kinetics across multi-analyte biosensor matrices. These platforms simultaneously quantify whole-blood electrolytes, blood urea nitrogen, creatinine, ionized calcium, and blood lactate from a single fingerstick drop of capillary blood. Advanced enzymatic mediator chemistries and multi-frequency hematocrit correction algorithms ensure that biosensor strips deliver accurate readings despite severe patient hematocrit variations, hypothermia, or elevated concentrations of interfering pharmacological agents.

Immunoassay platforms have achieved analytical parity with central laboratory core immunoanalyzers via single-use digital immunoassays and fluorescent lateral flow strips. Manufacturers have replaced conventional colloidal gold labels with quantum dots, europium fluorescent nanoparticles, and magnetic nanoparticles that yield high signal-to-noise ratios when read by compact optical sensors. Single-use lateral flow cassettes can now measure high-sensitivity cardiac Troponin I and Troponin T at single-digit picogram-per-milliliter concentrations, enabling emergency department clinicians to detect acute myocardial infarction within one hour of symptom onset without sending tubes to a central hospital core lab.

Multiplexing capability within a single disposable footprint has become a primary competitive differentiator. Rather than requiring healthcare providers to run multiple distinct tests, modern single-use cartridges feature multi-channel microfluidic arrays that interrogate a single patient swab or blood sample for comprehensive syndromic panels. Single-use respiratory panels now detect SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus simultaneously. In sexual health, single-use cartridges combine Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis detection on a single microfluidic chip, providing definitive syndromic diagnoses within a single outpatient visit.

Manufacturing methodologies have evolved through the integration of automated high-precision injection molding, precision laser ablation, and ultrasonic welding under Class 10,000 cleanroom standards. Reagent deposition technologies now utilize non-contact piezoelectric dispensing systems capable of delivering picoliter volumes of antibodies, enzymes, and fluorescent probes onto microfluidic reaction zones. Furthermore, developers are implementing integrated on-cartridge biological calibration controls that run concurrently with the clinical sample, validating reagent integrity, microfluidic channel filling, and optical reader calibration, thereby fulfilling CLIA quality control mandates in a single disposable test execution.

 

Segmentation Insights

The U.S. Single-Use Point-of-Care Testing Devices Market is segmented on the basis of product type, test type, sample matrix, clinical technology, end user, and regulatory classification.

 

• By Product Type

The U.S. Single-Use Point-of-Care Testing Devices Market by product type is segmented into Lateral Flow Test Strips & Cassettes, Microfluidic Lab-on-a-Chip Cartridges, Electrochemical Biosensor Strips, Rapid Molecular Diagnostic Cartridges, and Dipsticks & Visual Chemistries.

Lateral Flow Test Strips & Cassettes
Lateral flow test strips and cassettes represent the largest revenue-generating product category within the single-use market, accounting for USD 6.12 billion in 2026, up from USD 4.88 billion in 2023, USD 5.25 billion in 2024, and USD 5.67 billion in 2025. This segment is projected to reach USD 9.87 billion by 2032, expanding at an 8.27% CAGR from 2027 to 2032. Products within this domain include chromatographic immunoassay cassettes for infectious respiratory screening, rapid cardiac biomarker detection, human chorionic gonadotropin pregnancy testing, and multi-panel toxicology cups.

The substantial market share of this category is driven by its low unit cost, ease of use, long room-temperature shelf life, and fast results. The clinical architecture of lateral flow strips relies on nitrocellulose membranes, conjugated colloidal gold or fluorescent antibody labels, and capillary migration. Modern iterations integrate fluorescent nanoparticle labels that require compact digital optical readers, bridging the gap between qualitative visual screening and precise, quantitative diagnostic measurement. Their high adoption across urgent care centers, emergency departments, and retail clinics maintains steady, high-volume recurring consumable demand.

Microfluidic Lab-on-a-Chip Cartridges
Microfluidic lab-on-a-chip cartridges represent the second-largest and one of the highest-value product segments, generating USD 4.35 billion in 2026, following historical figures of USD 3.32 billion in 2023, USD 3.63 billion in 2024, and USD 3.97 billion in 2025. The category is projected to reach USD 7.42 billion by 2032, demonstrating a 9.31% CAGR from 2027 to 2032. These single-use consumables contain micro-scale channels, lyophilized chemical reagents, integrated calibration fluids, and electrochemical or optical sensor arrays designed to analyze whole blood specimens.

Demand is fueled by the clinical necessity for comprehensive, multi-analyte diagnostic panels at the point of care, including critical care blood gases, electrolytes, total bilirubin, coagulation profiles, and kidney function panels. Hospital critical care units, intensive care nurseries, and cardiovascular surgery suites depend on single-use microfluidic cartridges to deliver immediate physiological data without the cross-contamination risks associated with central laboratory benchtop blood gas analyzers. Advanced automated cleanroom manufacturing and precision ultrasonic sealing allow these cartridges to achieve high precision, supporting their adoption across acute hospital settings.

Electrochemical Biosensor Strips
Electrochemical biosensor strips accounted for USD 3.98 billion in 2026, having expanded from USD 3.22 billion in 2023, USD 3.45 billion in 2024, and USD 3.70 billion in 2025. By 2032, the segment is projected to achieve USD 6.28 billion, reflecting an 7.91% CAGR from 2027 to 2032. This product category encompasses disposable enzymatic biosensor strips utilized for blood glucose monitoring, blood ketone measurement, whole-blood lactate quantification, and point-of-care coagulation timing assays such as Prothrombin Time and International Normalized Ratio.

This category is sustained by massive, daily, non-discretionary utilization across millions of diabetic patients and inpatient hospital monitoring protocols. Single-use electrochemical strips incorporate screen-printed carbon or gold electrodes coated with specific oxidoreductase enzymes, electron-transfer mediators, and specialized polymer membranes that resist biofouling. Hospital-grade biosensor strips incorporate advanced error-detection circuitry to eliminate interference from maltose, acetaminophen, ascorbic acid, and extreme hematocrit fluctuations, maintaining high utilization across inpatient medical-surgical units, intensive care wards, and long-term care facilities.

Rapid Molecular Diagnostic Cartridges
Rapid molecular diagnostic cartridges represent the fastest-growing product category, accounting for USD 2.45 billion in 2026, up from USD 1.83 billion in 2023, USD 2.01 billion in 2024, and USD 2.22 billion in 2025. The segment is on track to achieve USD 4.54 billion by 2032, advancing at an 10.82% CAGR from 2027 to 2032. These single-use consumables contain microfluidic chambers engineered to perform complete sample-to-answer nucleic acid amplification testing, incorporating automated mechanical cell lysis, magnetic bead nucleic acid extraction, and micro-PCR or isothermal amplification reagents.

Growth is propelled by the clinical shift toward definitive molecular pathogen detection at the initial point of patient presentation. Rather than relying on lower-sensitivity rapid antigen tests, clinicians in emergency departments, urgent care networks, and outpatient pediatric clinics utilize single-use molecular cartridges to diagnose respiratory viruses, Group A Streptococcus, Clostridioides difficile, and sexually transmitted infections with high sensitivity and specificity. Lyophilization advances allow these complex enzymatic cartridges to be shipped and stored at room temperature, expanding their operational reach throughout decentralized clinical environments.

Dipsticks & Visual Chemistries
Dipsticks and visual chemistries generated USD 1.16 billion in 2026, following historical revenues of USD 0.93 billion in 2023, USD 1.01 billion in 2024, and USD 1.08 billion in 2025. The category is projected to reach USD 1.73 billion by 2032, growing at a 6.88% CAGR from 2027 to 2032. Products include plastic reagent strips with multiple chemical reagent pads for semi-quantitative urinalysis, urine microalbumin dipsticks, and fecal occult blood chemical cassettes.

While growing at a moderate rate relative to microfluidic and molecular categories, visual chemical dipsticks remain a fundamental diagnostic consumable utilized across every American primary care clinic, emergency department, and outpatient surgical center. Modern point-of-care utilization has evolved through the pairing of single-use urine dipsticks with compact, automated digital optical strip readers. These automated readers standardize color interpretation, eliminate operator visual subjectivity, and automatically upload semi-quantitative diagnostic data into electronic health records, ensuring stable consumable replacement demand.

 

• By Test Type

The U.S. Single-Use Point-of-Care Testing Devices Market by test type is segmented into Blood Glucose & Metabolic Monitoring, Infectious Disease Testing, Cardiac Markers & Critical Care Biomarkers, Coagulation & Hemostasis Testing, Drugs of Abuse & Toxicology, and Urinalysis & Fecal Biomarkers.

Blood Glucose & Metabolic Monitoring
Blood glucose and metabolic monitoring represents the largest single clinical application, accounting for USD 5.78 billion in 2026, following historical figures of USD 4.62 billion in 2023, USD 4.97 billion in 2024, and USD 5.36 billion in 2025. This segment is projected to reach USD 9.16 billion by 2032, expanding at an 8.00% CAGR from 2027 to 2032. Diagnostic testing encompasses blood glucose strips, blood ketone test strips, lactate cartridges, basic metabolic panels, and point-of-care glycated hemoglobin test cartridges.

The large revenue footprint of this segment is tied to the management of diabetes and metabolic decompensation across inpatient and outpatient care settings. In hospital environments, bedside blood glucose monitoring remains the most frequently executed single-use test, performed multiple times daily on surgical, intensive care, and general ward patients to maintain tight glycemic control and reduce surgical-site infections. Furthermore, single-use lactate cartridges have become standard tools within emergency departments and intensive care units for the rapid identification and guided resuscitation of clinical sepsis under international Surviving Sepsis Campaign guidelines.

Infectious Disease Testing
Infectious disease testing represents the second-largest test category, generating USD 4.69 billion in 2026, having grown from USD 3.63 billion in 2023, USD 3.94 billion in 2024, and USD 4.30 billion in 2025. The category is projected to achieve USD 8.16 billion by 2032, demonstrating a 9.68% CAGR from 2027 to 2032. Testing menus include rapid single-use tests for respiratory viruses such as Influenza, SARS-CoV-2, and RSV; Group A Streptococcus; viral hepatitis; human immunodeficiency virus; and sexually transmitted infections.

The expansion of this segment is sustained by the permanent clinical adoption of multiplex syndromic testing across outpatient networks. Outpatient clinicians rely on single-use multiplex cassettes that differentiate between clinically indistinguishable respiratory infections from a single swab, informing immediate antiviral prescription decisions and curbing inappropriate antibiotic utilization. Concurrently, public health initiatives promoting rapid routine screening for HIV and Hepatitis C in emergency departments, community health centers, and addiction clinics drive high-volume procurement of single-use lateral flow test cassettes.

Cardiac Markers & Critical Care Biomarkers
Cardiac markers and critical care biomarkers accounted for USD 3.07 billion in 2026, up from USD 2.37 billion in 2023, USD 2.58 billion in 2024, and USD 2.81 billion in 2025. By 2032, the category is projected to reach USD 5.37 billion, reflecting a 9.77% CAGR from 2027 to 2032. Diagnostic analytes include high-sensitivity cardiac Troponin I and Troponin T, B-type Natriuretic Peptide, N-terminal pro-B-type Natriuretic Peptide, D-dimer for pulmonary embolism and deep vein thrombosis exclusion, and Creatine Kinase-MB.

Clinical demand is anchored in the necessity for rapid emergency department triage of acute coronary syndromes, pulmonary embolism, and decompensated heart failure. Delivering quantitative high-sensitivity troponin results within fifteen minutes directly at the bedside enables emergency physicians to implement rapid rule-in and rule-out algorithms, identifying acute myocardial infarction early and discharging low-risk patients without unnecessary multi-hour laboratory waits. Single-use D-dimer cassettes facilitate the rapid exclusion of thromboembolic events, optimizing clinical decision-making and avoiding costly, non-emergent computerized tomography pulmonary angiography scans.

Coagulation & Hemostasis Testing
Coagulation and hemostasis testing generated USD 1.98 billion in 2026, following historical levels of USD 1.58 billion in 2023, USD 1.70 billion in 2024, and USD 1.83 billion in 2025. The segment is on track to reach USD 3.19 billion by 2032, growing at an 8.27% CAGR from 2027 to 2032. Diagnostic platforms include single-use test strips and microfluidic cartridges for Prothrombin Time and International Normalized Ratio, Activated Clotting Time, Activated Partial Thromboplastin Time, and disposable viscoelastic hemostasis testing cartridges.

This segment is driven by widespread oral anticoagulation therapy monitoring alongside intraoperative hemostatic management within cardiac operating rooms, catheterization labs, and trauma resuscitation bays. Single-use PT/INR strips allow anticoagulation clinics and home-care patients to monitor vitamin K antagonist therapy safely. In acute surgical and trauma settings, single-use microfluidic ACT and viscoelastic hemostasis cartridges provide immediate quantification of platelet function, fibrinogen levels, and clot strength, enabling targeted transfusion of blood products and reducing overall blood component wastage during open-heart surgery and major polytrauma interventions.

Drugs of Abuse & Toxicology
Drugs of abuse and toxicology accounted for USD 1.45 billion in 2026, having expanded from USD 1.17 billion in 2023, USD 1.26 billion in 2024, and USD 1.35 billion in 2025. The category is projected to reach USD 2.27 billion by 2032, exhibiting an 7.76% CAGR from 2027 to 2032. Products encompass single-use multi-panel urine screening cups, rapid saliva toxicology cassettes, and single-use lateral flow test strips detecting opioids, fentanyl, methamphetamine, cocaine, cannabinoids, benzodiazepines, and synthetic illicit substances.

Procurement is supported by emergency department overdose triage, hospital behavioral health admissions, workplace pre-employment screening, criminal justice monitoring, and substance abuse rehabilitation center admissions. The clinical rise of synthetic fentanyl analogs has driven emergency departments to deploy ultra-sensitive, single-use lateral flow fentanyl test strips to rapidly guide naloxone dosing and clinical stabilization protocols. Multi-panel disposable urine testing cups with integrated temperature strips and adulteration test pads represent standard, tamper-resistant diagnostic consumables throughout the U.S. healthcare and occupational compliance infrastructure.

Urinalysis & Fecal Biomarkers
Urinalysis and fecal biomarkers generated USD 1.09 billion in 2026, following historical revenues of USD 0.86 billion in 2023, USD 0.93 billion in 2024, and USD 1.01 billion in 2025. The segment is projected to achieve USD 1.69 billion by 2032, expanding at a 7.58% CAGR from 2027 to 2032. This category comprises multi-parameter urine test strips, microalbumin/creatinine ratio test strips, fecal occult blood immunochemical test cassettes, and single-use fecal calprotectin assay cartridges.

Demand is sustained by routine primary care physical examinations, outpatient diabetes nephropathy surveillance, and colorectal cancer screening initiatives. Single-use urinalysis strips facilitate rapid detection of urinary tract infections, hematuria, proteinuria, and hepatic dysfunction during initial clinic triage. Fecal immunochemical test cassettes have become the standard decentralized, single-use non-invasive screening tool for early colorectal neoplasia, driving high-volume consumable purchasing across hospital outpatient clinics, accountable care organizations, and community healthcare initiatives.

 

• By Sample Matrix

The U.S. Single-Use Point-of-Care Testing Devices Market by sample matrix is segmented into Whole Blood & Capillary Fingerstick Blood, Nasopharyngeal, Nasal & Throat Swabs, Urine & Biological Fluids, and Oral Fluid & Saliva.

Whole Blood & Capillary Fingerstick Blood
Whole blood and capillary fingerstick blood represents the largest sample matrix category, accounting for USD 9.57 billion in 2026, up from USD 7.48 billion in 2023, USD 8.11 billion in 2024, and USD 8.81 billion in 2025. This segment is projected to reach USD 16.03 billion by 2032, advancing at an 8.99% CAGR from 2027 to 2032. Applications include single-use blood glucose strips, blood gas microfluidic cards, high-sensitivity cardiac biomarker cartridges, rapid lactate and lipid panels, and point-of-care hemostasis cartridges.

The dominance of whole blood matrices stems from the fact that circulating blood provides immediate, real-time insight into acute systemic pathophysiology. The engineering breakthrough enabling this segment’s scale is the integration of on-chip plasma separation membranes and specialized microfluidic filtration channels within single-use cartridges. These microfluidic architectures automatically filter out red and white blood cells from whole capillary drops or venous aliquots without requiring mechanical centrifugation, delivering pristine plasma fractions directly to sensor zones. This allows bedside clinicians to bypass core-lab phlebotomy tubes and run advanced clinical chemistry and immunoassay panels from a single fingerstick or arterial puncture.

Nasopharyngeal, Nasal & Throat Swabs
Nasopharyngeal, nasal, and throat swabs represent the second-largest matrix category, generating USD 4.88 billion in 2026, having grown from USD 3.86 billion in 2023, USD 4.18 billion in 2024, and USD 4.51 billion in 2025. The category is projected to reach USD 8.08 billion by 2032, demonstrating an 8.77% CAGR from 2027 to 2032. This segment encompasses single-use lateral flow cassettes and disposable molecular cartridges used to diagnose acute upper respiratory tract infections, including Influenza, SARS-CoV-2, RSV, and Streptococcus pyogenes.

Procurement is driven by the volume of pediatric, adult, and geriatric patients presenting with acute respiratory symptoms across urgent care centers, emergency departments, and outpatient primary care clinics. Manufacturers have optimized single-use cartridges to accept direct swab eluates, incorporating self-contained buffer ampoules that pierce upon closure, instantly lysing pathogens and releasing viral RNA or bacterial antigens directly into reaction channels. The shift toward comfortable, anterior nasal swab collection protocols has further enhanced patient acceptance, driving consistent multi-million-unit consumable replenishment cycles across winter respiratory seasons.

Urine & Biological Fluids
Urine and biological fluids accounted for USD 2.62 billion in 2026, following historical figures of USD 2.11 billion in 2023, USD 2.27 billion in 2024, and USD 2.44 billion in 2025. The segment is on track to achieve USD 4.14 billion by 2032, expanding at a 7.93% CAGR from 2027 to 2032. Products include single-use urinalysis strips, human chorionic gonadotropin pregnancy cassettes, multi-drug screening cups, microalbumin strips, and specialized cartridges for cerebrospinal, pleural, or peritoneal fluid assessment.

Urine remains a standard diagnostic medium due to its completely non-invasive collection protocol, abundant sample volume, and proven clinical diagnostic utility for metabolic, renal, toxicology, and reproductive health assessments. Single-use multi-parameter test strips and cassettes provide immediate insight into proteinuria, glycosuria, nitrites, leukocyte esterase, and drug metabolites. In emergency departments and outpatient gynecology, single-use urine pregnancy test cassettes are universally utilized prior to radiography, medication administration, or surgical procedures, ensuring steady consumable utilization across inpatient and outpatient care networks.

Oral Fluid & Saliva
Oral fluid and saliva generated USD 0.99 billion in 2026, up from USD 0.73 billion in 2023, USD 0.79 billion in 2024, and USD 0.88 billion in 2025. By 2032, the category is projected to achieve USD 1.59 billion, growing at an 8.22% CAGR from 2027 to 2032. Applications include rapid HIV oral fluid screening cassettes, point-of-care saliva drug screening devices, rapid viral antigen saliva strips, and emerging salivary hormone testing platforms.

Oral fluid is expanding as an alternative diagnostic matrix due to its non-invasive collection method and low risk of specimen adulteration compared to urine in toxicology screening. Workplace drug testing, roadside law enforcement screening, and community infectious disease outreach programs utilize single-use oral fluid collection swabs that integrate directly into lateral flow cassettes. Advancements in microfluidic sample filtration have addressed historical challenges associated with saliva viscosity and mucin interference, enabling accurate quantitative detection of biomarkers and expanding the commercial role of saliva-based disposable testing platforms.

 

• By Clinical Technology

The U.S. Single-Use Point-of-Care Testing Devices Market by clinical technology is segmented into Rapid Immunoassays, Electrochemical Biosensors, Single-Use Molecular Diagnostics, and Optical & Colorimetric Systems.

Rapid Immunoassays
Rapid immunoassays represent the largest technology classification, accounting for USD 7.22 billion in 2026, following historical levels of USD 5.76 billion in 2023, USD 6.20 billion in 2024, and USD 6.69 billion in 2025. The category is projected to reach USD 11.75 billion by 2032, expanding at an 8.46% CAGR from 2027 to 2032. This technology group encompasses colloidal gold lateral flow cassettes, fluorescent dye-conjugated immunoassays, quantum dot test strips, and single-use chemiluminescent micro-cartridges.

The dominant market share of rapid immunoassays is sustained by their versatility across cardiac biomarkers, infectious diseases, hormones, and toxicology screening. Advanced lateral flow configurations incorporate high-affinity monoclonal antibodies, fluorescent europium chelates, and time-resolved fluorescence optical readers that achieve sensitivity levels comparable to central core laboratory analyzers. The low manufacturing cost of plastic cassettes, combined with ambient-temperature shelf stability, positions rapid single-use immunoassays as the primary diagnostic platform across American urgent care centers, emergency departments, and outpatient clinics.

Electrochemical Biosensors
Electrochemical biosensors represent the second-largest technology segment, generating USD 5.24 billion in 2026, having grown from USD 4.19 billion in 2023, USD 4.51 billion in 2024, and USD 4.86 billion in 2025. The category is on track to achieve USD 8.44 billion by 2032, demonstrating an 8.27% CAGR from 2027 to 2032. Platforms utilize amperometric, potentiometric, and conductometric biosensing mechanisms implemented on single-use screen-printed electrodes and microfluidic cards.

Electrochemical biosensing is the analytical backbone for bedside blood glucose testing, critical care blood gas analysis, electrolyte panels, blood lactate measurement, and coagulation monitoring. These single-use sensors convert specific biochemical reactions, such as the enzymatic oxidation of glucose or the potentiometric equilibrium of potassium ions across an ion-selective membrane, directly into calibrated electrical current or potential. High analytical reproducibility, micro-sample volume requirements, and millisecond electronic response times make electrochemical biosensor strips indispensable across high-acuity hospital operating rooms, intensive care units, and outpatient diabetic management.

Single-Use Molecular Diagnostics
Single-use molecular diagnostics represents the fastest-expanding technology group, accounting for USD 3.07 billion in 2026, up from USD 2.23 billion in 2023, USD 2.47 billion in 2024, and USD 2.76 billion in 2025. The segment is projected to achieve USD 5.86 billion by 2032, advancing at an 11.38% CAGR from 2027 to 2032. Technologies include microfluidic reverse-transcription polymerase chain reaction cartridges, Loop-Mediated Isothermal Amplification cards, and Recombinase Polymerase Amplification disposable cassettes.

This technology group represents the leading edge of decentralized diagnostic innovation, bringing reference-laboratory-grade sensitivity directly to outpatient triage desks. By automating cell lysis, nucleic acid purification, enzymatic amplification, and fluorometric detection within a single self-contained disposable cartridge, these devices eliminate the risk of PCR amplicon cross-contamination in non-laboratory environments. The availability of CLIA-waived molecular test cartridges for syndromic respiratory and sexual health panels has accelerated adoption across urgent care clinics, workplace health centers, and emergency department triage bays.

Optical & Colorimetric Systems
Optical and colorimetric systems generated USD 2.53 billion in 2026, following historical figures of USD 2.00 billion in 2023, USD 2.17 billion in 2024, and USD 2.33 billion in 2025. By 2032, the category is projected to reach USD 3.79 billion, exhibiting a 6.97% CAGR from 2027 to 2032. This foundational segment comprises single-use multi-reagent urinalysis dipsticks, colorimetric enzymatic cards for clinical chemistry analytes, spectrophotometric micro-cuvettes for point-of-care hemoglobin quantification, and visual immunochemical cassettes.

The stable growth of optical and colorimetric systems is supported by their widespread utilization in routine clinical workflows. Plastic micro-cuvettes containing dry reagents for instant spectrophotometric hemoglobin measurement are standard across outpatient surgical pre-admission clinics, pediatric screening visits, and blood donation collection centers. Point-of-care colorimetric urinalysis strips read by compact automated reflectance photometers provide standardized, objective semi-quantitative screening for renal disease, liver dysfunction, and metabolic disorders across hospital outpatient clinics and community health centers.

 

• By End User

The U.S. Single-Use Point-of-Care Testing Devices Market by end user is segmented into Hospital Emergency Departments & Intensive Care Units, Physician Office Laboratories & Outpatient Clinics, Urgent Care Centers & Retail Clinics, Ambulatory Surgical Centers & Dialysis Centers, and Home Care Settings & Patient Self-Testing.

Hospital Emergency Departments & Intensive Care Units
Hospital emergency departments and intensive care units represent the largest commercial end-user category, accounting for USD 6.68 billion in 2026, up from USD 5.17 billion in 2023, USD 5.62 billion in 2024, and USD 6.13 billion in 2025. This segment is projected to reach USD 11.37 billion by 2032, expanding at an 9.27% CAGR from 2027 to 2032. These acute care environments consume high volumes of single-use high-sensitivity cardiac troponin cartridges, blood gas microfluidic cards, lactate test strips, and rapid molecular respiratory panels.

The primacy of this end-user segment is tied to the critical need for diagnostic speed, high patient acuity, and constant clinical throughput. Emergency departments manage time-sensitive conditions including acute myocardial infarction, acute ischemic stroke, pulmonary embolism, severe sepsis, and diabetic ketoacidosis. Clinicians cannot wait for central core laboratory batching. Single-use cartridges run at bedside allow emergency physicians to formulate definitive triage decisions, initiate life-saving medical management, and streamline inpatient admissions. Because these platforms are discarded immediately after use, they eliminate cross-contamination between patients in crowded emergency bays, complying with hospital infection control mandates.

Physician Office Laboratories & Outpatient Clinics
Physician office laboratories and outpatient clinics accounted for USD 4.33 billion in 2026, having grown from USD 3.46 billion in 2023, USD 3.72 billion in 2024, and USD 4.01 billion in 2025. The category is projected to achieve USD 6.92 billion by 2032, demonstrating a 8.12% CAGR from 2027 to 2032. Facilities include private primary care practices, multi-specialty group practices, community health clinics, and cardiology and endocrinology outpatient facilities.

Independent and health-system-affiliated physician practices represent a stable, high-volume consumer of CLIA-waived single-use testing devices. Outpatient physicians utilize single-use glucose strips, rapid Strep A cassettes, influenza/COVID-19 antigen strips, urinalysis dipsticks, and point-of-care HbA1c cartridges to assess patients and initiate therapies during a single office visit. This eliminates the need for separate phlebotomy appointments and follow-up consultation calls. Fee-for-service reimbursement through CPT codes allows physician practices to capture ancillary diagnostic revenue while improving patient care compliance and satisfaction.

Urgent Care Centers & Retail Clinics
Urgent care centers and retail clinics generated USD 3.61 billion in 2026, following historical figures of USD 2.75 billion in 2023, USD 3.01 billion in 2024, and USD 3.30 billion in 2025. The segment is on track to reach USD 6.38 billion by 2032, advancing at an 10.00% CAGR from 2027 to 2032. This category comprises over 14,000 urgent care clinics and major retail walk-in health centers located across the United States.

Urgent care facilities are among the fastest-expanding end-user markets for single-use point-of-care diagnostics. These facilities manage acute episodic illness, minor trauma, and occupational health screening without the extensive physical infrastructure of traditional hospitals. Their business model requires patient encounter times under forty-five minutes, necessitating single-use rapid molecular cartridges and lateral flow cassettes that deliver definitive results in under twenty minutes. Single-use test cartridges require minimal technician training, eliminate liquid biohazard disposal complexities, and generate attractive reimbursement margins, making them central to urgent care operations.

Ambulatory Surgical Centers & Dialysis Centers
Ambulatory surgical centers and dialysis centers accounted for USD 1.81 billion in 2026, having expanded from USD 1.45 billion in 2023, USD 1.56 billion in 2024, and USD 1.68 billion in 2025. By 2032, the category is projected to reach USD 2.89 billion, reflecting an 8.11% CAGR from 2027 to 2032. Products include single-use coagulation cartridges, whole-blood electrolyte cards, pregnancy test cassettes, and point-of-care hemoglobin micro-cuvettes.

The rapid migration of surgical procedures from inpatient hospital suites to outpatient ambulatory surgical centers drives steady device utilization in this segment. Before outpatient surgical procedures, ASC clinicians must verify hemostatic competency, confirm the absence of pregnancy, and assess electrolyte balance. Single-use point-of-care cartridges allow surgical staff to confirm pre-operative patient clearance minutes before anesthesia induction, avoiding procedural cancellations and optimizing operating room scheduling efficiency. In outpatient dialysis centers, single-use electrolyte and hemoglobin strips guide fluid removal and erythropoietin dosing during treatment sessions.

Home Care Settings & Patient Self-Testing
Home care settings and patient self-testing generated USD 1.63 billion in 2026, up from USD 1.32 billion in 2023, USD 1.41 billion in 2024, and USD 1.52 billion in 2025. The segment is projected to achieve USD 2.28 billion by 2032, growing at a 5.75% CAGR from 2027 to 2032. Consumable devices include single-use blood glucose test strips, over-the-counter rapid viral antigen tests, home pregnancy and ovulation cassettes, and single-use PT/INR strips for anticoagulation self-monitoring.

Consumer preference for direct, at-home diagnostic screening, expanded over-the-counter regulatory approvals, and the growth of hospital-at-home programs sustain this market. Patients managing chronic diseases rely on single-use biosensor strips to monitor glycemic control and coagulation parameters, transmitting results directly to clinical care teams via smartphone interfaces. Mobile paramedicine and home visiting nurses utilize portable single-use test kits to triage acute complaints in homebound geriatric patients, reducing avoidable emergency department admissions.

 

• By Regulatory Classification

The U.S. Single-Use Point-of-Care Testing Devices Market by regulatory classification is segmented into CLIA-Waived Single-Use Devices and CLIA Moderate-Complexity Single-Use Cartridges & Devices.

CLIA-Waived Single-Use Devices
CLIA-waived single-use devices represent the dominant regulatory category, accounting for USD 13.91 billion in 2026, following historical figures of USD 10.84 billion in 2023, USD 11.77 billion in 2024, and USD 12.80 billion in 2025. This segment is projected to reach USD 23.48 billion by 2032, expanding at an 9.12% CAGR from 2027 to 2032. Products include simple lateral flow test strips, single-use blood glucose biosensors, CLIA-waived molecular test cartridges, and disposable urinalysis dipsticks.

The substantial market share of CLIA-waived single-use devices stems from their broad operational accessibility across the U.S. healthcare delivery system. Under the Clinical Laboratory Improvement Amendments of 1988, facilities possessing a Certificate of Waiver can perform simple diagnostic testing with minimal risk of an erroneous result. There are over 280,000 CLIA-waived testing sites across the United States, including physician offices, urgent care centers, retail clinics, skilled nursing homes, and outpatient surgical centers. By engineering single-use cartridges with integrated fail-safes, automated microfluidics, and straightforward visual or digital readouts, medtech vendors unlock access to this broad commercial footprint without requiring accredited laboratory testing personnel.

CLIA Moderate-Complexity Single-Use Cartridges & Devices
CLIA moderate-complexity single-use cartridges and devices accounted for USD 4.15 billion in 2026, up from USD 3.34 billion in 2023, USD 3.58 billion in 2024, and USD 3.84 billion in 2025. The category is on track to achieve USD 6.36 billion by 2032, demonstrating a 7.38% CAGR from 2027 to 2032. Devices within this domain include specialized critical care blood gas and electrolyte microfluidic cartridges, automated viscoelastic coagulation test cards, specialized toxicology multi-analyte panels, and certain multiplex molecular panels.

While subject to more stringent personnel, quality control, and proficiency testing standards than waived devices, moderate-complexity single-use cartridges remain vital across acute hospital environments, including emergency departments, cardiac catheterization laboratories, and intensive care units. These single-use cartridges measure complex physiological parameters, including arterial blood gases, base excess, ionized magnesium, and high-tier hemostasis kinetics, requiring trained clinical nursing or respiratory therapy personnel. Their single-use design minimizes maintenance and calibration overhead compared to central core laboratory equipment, maintaining steady demand within high-acuity hospital networks.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Single-Use Point-of-Care Testing Devices Market is geographically segmented into four commercial regions: the South, the West, the Midwest, and the Northeast. Regional market performance is governed by population demographics, chronic disease prevalence, healthcare facility density, state-level regulatory and reimbursement environments, the consolidation of acute and urgent care health networks, and localized emergency department utilization patterns.

South

The South represents the largest commercial regional market for single-use point-of-care testing devices in the United States, generating USD 6.78 billion in 2026, up from historical levels of USD 5.28 billion in 2023, USD 5.73 billion in 2024, and USD 6.23 billion in 2025. The Southern regional market is projected to reach USD 11.38 billion by 2032, expanding at an 9.02% CAGR from 2027 to 2032. Commercial leadership in the South is underpinned by its large population concentration, high rates of chronic cardiometabolic disease, rapid suburban population growth, and the aggressive expansion of private urgent care networks and consolidated hospital health systems. The region displays elevated incidences of Type 2 diabetes, end-stage renal disease, cardiovascular morbidity, and stroke, creating non-discretionary clinical demand for single-use glucose strips, cardiac biomarker cartridges, and critical care blood gas consumables.

Texas serves as the primary economic engine for single-use point-of-care testing within the Southern region. Supported by a population surpassing thirty-one million residents, Texas features dense concentrations of acute hospital systems, independent emergency centers, and corporate urgent care networks across the Houston, Dallas-Fort Worth, Austin, and San Antonio metropolitan areas. The Texas Medical Center in Houston, the largest medical complex in the world, consumes substantial volumes of single-use critical care microfluidic cartridges, viscoelastic coagulation cards, and high-sensitivity cardiac troponin cassettes across its emergency and surgical suites. Furthermore, Texas maintains an extensive network of freestanding, licensed emergency medical centers that rely on CLIA-waived single-use testing devices to achieve rapid patient triage without supporting central core laboratories. High diabetes prevalence across South Texas and along the Rio Grande Valley drives significant demand for single-use electrochemical glucose and ketone test strips.

Florida represents the second-largest state market in the South, shaped by its large geriatric population, high Medicare beneficiary density, and expansive hospital and urgent care networks across Miami, Tampa, Orlando, and Jacksonville. Florida’s high population of senior residents translates into elevated hospital admissions for acute coronary syndromes, congestive heart failure decompensation, acute respiratory distress, and chronic kidney disease. Consequently, emergency departments and cardiology clinics across Florida invest heavily in single-use high-sensitivity troponin assays, point-of-care B-type natriuretic peptide cartridges, and blood gas cards to optimize clinical workflow efficiency. Florida’s urgent care and walk-in clinic market is among the most consolidated in the country, driven by high tourist volumes and retiree health needs, creating recurring demand for single-use respiratory viral panels and rapid Strep cassettes.

North Carolina and Georgia function as dynamic medtech hubs, propelled by growing urban healthcare corridors and research-driven hospital networks. The Research Triangle metropolitan area in North Carolina, encompassing Raleigh, Durham, and Chapel Hill, anchored by Duke University Health System and UNC Health, alongside the Charlotte metropolitan area anchored by Atrium Health, demonstrates high adoption of single-use molecular cartridges and digital immunoassay systems. Georgia, centered on the Atlanta metropolitan region and anchored by Emory Healthcare and Wellstar Health System, displays substantial purchasing of single-use point-of-care diagnostics across emergency departments, pediatric urgent care chains, and ambulatory surgical centers. Both states have expanded community and rural healthcare access through decentralized clinics utilizing CLIA-waived disposable testing to address healthcare delivery disparities.

Tennessee, Virginia, and the Gulf Coast states, including Louisiana, Alabama, and Mississippi, provide strong recurring demand across acute and outpatient care channels. Tennessee, with its major corporate healthcare headquarters in Nashville, such as HCA Healthcare, acts as an operational testbed for standardized hospital fleet procurement of single-use point-of-care diagnostic cartridges. Virginia features high-density, well-funded healthcare networks across Northern Virginia and the Richmond corridor, exhibiting robust procurement of single-use cardiac and molecular testing consumables. Across Alabama, Mississippi, and Louisiana, elevated rates of cardiovascular disease, diabetes, and metabolic syndrome sustain steady utilization of disposable biosensor strips, capillary blood collection devices, and rapid infectious disease screening tests in community health clinics and regional trauma centers.

The commercial landscape across the South requires device vendors to balance supply agreements with large hospital systems alongside distribution through retail and urgent care channels. While academic medical centers in urban areas procure advanced single-use molecular multiplexing cartridges and digital cardiac cassettes, extensive rural clinics across the South require cost-effective, room-temperature-stable CLIA-waived test strips supported by dependable distribution networks. Manufacturers that execute hybrid commercial models, pairing direct enterprise hospital contracting with robust regional medical-surgical distribution agreements, secure durable competitive advantages across the South.

West

The West represents the fastest-growing single-use point-of-care testing devices region through 2032, accounting for USD 4.97 billion in 2026, following historical revenues of USD 3.86 billion in 2023, USD 4.19 billion in 2024, and USD 4.56 billion in 2025. The Western market is projected to reach USD 8.38 billion by 2032, demonstrating an 9.10% CAGR from 2027 to 2032. The region’s growth profile is driven by early clinical adoption of advanced microfluidic and molecular technologies, progressive state healthcare policies, well-funded health systems, and an active outpatient retail clinic landscape.

California represents the primary commercial anchor of the Western region and the largest single state market for single-use point-of-care diagnostic devices in the nation. Supported by a population approaching thirty-nine million, California features innovative healthcare networks, academic health systems, and health maintenance organizations, including Kaiser Permanente, Sutter Health, Cedars-Sinai, and UCLA Health. These organizations have systematically integrated single-use point-of-care testing into their outpatient clinics, urgent care centers, and emergency departments to shorten patient wait times and fulfill state healthcare quality mandates. The Los Angeles basin, Orange County, San Diego, and the San Francisco Bay Area contain dense networks of urgent care clinics that utilize single-use molecular cartridges for respiratory and sexually transmitted infection screening. California’s state regulatory environment encourages early adoption of digital health interfaces, driving demand for single-use test cartridges that connect directly with smartphone reader applications and cloud-based electronic medical records.

Washington and Oregon represent mature, progressive diagnostic markets characterized by integrated healthcare delivery systems and strong public health infrastructure. The Seattle metropolitan area, alongside Portland, exhibits high adoption of single-use molecular diagnostics across primary and urgent care environments. Healthcare networks such as UW Medicine and Providence Health demonstrate sustained procurement of single-use syndromic respiratory cartridges, high-sensitivity cardiac cassettes, and disposable whole-blood microfluidic panels. State-level public health screening programs for viral hepatitis and HIV drive high-volume purchasing of single-use lateral flow test cassettes across community clinics and street-medicine outreach initiatives throughout the Pacific Northwest.

Colorado, Arizona, and Utah represent expanding interior Western markets, fueled by substantial population influxes, growing technology corridors, and the expansion of suburban health centers. Colorado’s Front Range, stretching from Fort Collins through Denver to Colorado Springs, features advanced healthcare systems such as UCHealth and Centura Health that utilize single-use point-of-care testing across high-altitude emergency departments and specialized trauma centers. In Arizona, anchored by the Phoenix-Scottsdale metropolitan region and Tucson, healthcare networks cater to a growing retiree population, driving demand for single-use troponin cartridges, blood gas cards, and diabetes biosensor strips. Utah, supported by Intermountain Health in Salt Lake City, represents a benchmark for clinical workflow efficiency, where single-use diagnostic consumables are deployed to streamline outpatient triage and reduce unnecessary hospital admissions. Nevada, Idaho, Montana, and Wyoming contribute steady market expansion, utilizing single-use CLIA-waived diagnostic cartridges to deliver clinical testing capabilities to distributed rural and resort communities.

The Western market environment is characterized by strict expectations regarding waste management, analytical performance, and integrated digital connectivity. Healthcare systems in California and the Pacific Northwest scrutinize plastic packaging and cartridge disposability, favoring vendors that engineer compact single-use cartridges with minimized plastic mass and eco-conscious packaging. Diagnostic suppliers that deliver high-sensitivity analytical performance, room-temperature reagent stability, and automated data synchronization into enterprise health records secure superior conversion rates across Western healthcare organizations.

Midwest

The Midwest represents a mature, highly resilient market for single-use point-of-care testing devices, generating USD 3.54 billion in 2026, up from historical levels of USD 2.82 billion in 2023, USD 3.04 billion in 2024, and USD 3.28 billion in 2025. The Midwestern market is projected to reach USD 5.66 billion by 2032, expanding at an 8.13% CAGR from 2027 to 2032. The region’s clinical diagnostic demand is balanced between dense urban medical centers across major industrial cities and expansive community hospital and rural clinic networks throughout the agricultural heartland.

Illinois and Ohio represent the primary revenue drivers within the Midwestern landscape. The Chicago metropolitan area encompasses one of the densest and most lucrative healthcare markets in the United States, featuring prominent health systems such as Northwestern Medicine, Rush University System for Health, and the University of Chicago Medicine. Emergency departments and outpatient clinics across the Chicago corridor consume substantial volumes of single-use cardiac troponin cartridges, rapid molecular respiratory panels, and electrochemical blood gas cards to manage patient volumes. Ohio features an established clinical care infrastructure anchored by Cleveland Clinic, OhioHealth, and The Ohio State University Wexner Medical Center. Cleveland Clinic’s extensive regional ambulatory and emergency care networks utilize standardized fleets of single-use point-of-care test devices to maintain consistent clinical diagnostic standards across hospital and outpatient facilities.

Michigan, Indiana, and Wisconsin provide steady market demand across tertiary academic medical centers, suburban health systems, and rural critical access hospitals. Michigan’s healthcare market, centered on Detroit, Ann Arbor, and Grand Rapids, anchored by Corewell Health and the University of Michigan Health System, exhibits sustained demand for single-use surgical and critical care diagnostic cartridges, including activated clotting time and viscoelastic hemostasis consumables. Indiana hosts major pharmaceutical and medical technology manufacturing operations and healthcare systems in Indianapolis, driving consistent procurement of single-use glucose biosensor strips, cardiac biomarker cassettes, and urinalysis strips. Wisconsin, anchored by Advocate Aurora Health and the University of Wisconsin Health System, demonstrates strong uptake of single-use CLIA-waived diagnostic cartridges across outpatient clinics and critical access hospitals, ensuring rapid diagnostic capabilities in regional care facilities.

Minnesota, Iowa, Missouri, and the Plains States, including Kansas, Nebraska, and the Dakotas, represent critical components of the Midwestern healthcare ecosystem. Minnesota hosts world-renowned healthcare institutions, led by the Mayo Clinic in Rochester, alongside Fairview Health Services in the Twin Cities. The Mayo Clinic sets clinical standards for point-of-care diagnostic accuracy, acting as an evaluation proving ground for next-generation single-use microfluidic and molecular cartridges. Iowa, Missouri, and the Plains States feature extensive networks of Critical Access Hospitals and Rural Health Clinics that rely on single-use CLIA-waived cartridges to conduct point-of-care blood chemistry, cardiac, and infectious disease testing without full-time on-site laboratory technologists.

Procurement behavior across the Midwest is characterized by disciplined capital budgeting, a focus on total cost of ownership, and an emphasis on demonstrated clinical efficacy. Independent community hospitals and consolidated health systems evaluate consumable costs per reportable patient result. Midwestern healthcare buyers favor reliable single-use testing cartridges with low operational failure rates, simple test protocols, and clear manufacturer customer support, rewarding vendors that offer transparent pricing and reliable consumable delivery schedules.

Northeast

The Northeast represents a clinically advanced regional market, accounting for USD 2.77 billion in 2026, having grown from USD 2.22 billion in 2023, USD 2.39 billion in 2024, and USD 2.57 billion in 2025. The Northeastern market is projected to reach USD 4.42 billion by 2032, demonstrating an 8.09% CAGR from 2027 to 2032. Although geographically more compact than other regions, the Northeast possesses the nation’s highest concentration of elite academic medical centers, teaching hospitals, and medical research facilities per square mile, alongside dense metropolitan patient populations.

New York represents the economic cornerstone of the Northeastern single-use point-of-care testing market. The New York City metropolitan area, encompassing Manhattan, Brooklyn, Queens, the Bronx, Long Island, and Westchester County, features major health systems, including NewYork-Presbyterian, Mount Sinai Health System, NYU Langone Health, Montefiore Health System, and Northwell Health. These institutions manage some of the busiest emergency departments and ambulatory clinics in the world, generating significant demand for single-use high-sensitivity cardiac troponin cartridges, rapid blood gas and electrolyte cards, and single-use molecular infectious disease panels. Given high urban real estate costs, healthcare facilities in New York City prioritize compact single-use diagnostic platforms that eliminate dedicated laboratory footprints, allowing rapid testing to occur directly within emergency triage bays and urgent care examination rooms. Upstate New York, supported by health systems in Albany, Rochester, and Buffalo, maintains steady utilization of single-use diagnostics across community hospitals and outpatient specialty clinics.

Pennsylvania represents the second-largest state market within the Northeast, anchored by dense healthcare delivery corridors in Philadelphia and Pittsburgh. Philadelphia hosts major academic health systems, including Penn Medicine, Jefferson Health, and Temple Health, which utilize single-use microfluidic cartridges and digital immunoassay cassettes across trauma centers and surgical intensive care units. In Western Pennsylvania, the University of Pittsburgh Medical Center commands an extensive, integrated network of acute care hospitals, outpatient surgical centers, and community clinics that deploy single-use point-of-care diagnostic devices to standardize clinical protocols and lower hospital readmission rates.

Massachusetts, New Jersey, and Connecticut represent affluent healthcare markets distinguished by research institutions, extensive life sciences corridors, and progressive healthcare delivery models. The Boston metropolitan area, anchored by Mass General Brigham, Beth Israel Lahey Health, and Boston Children’s Hospital, represents an important center for clinical diagnostic innovation. These institutions adopt next-generation single-use molecular test cartridges and microfluidic whole-blood analyzers early in their commercial lifecycles. New Jersey, with its dense suburban population and concentration of pharmaceutical and biotechnology firms, exhibits high per-capita utilization of single-use point-of-care testing across urgent care clinics, primary care networks, and outpatient surgical centers. Connecticut’s Gold Coast and the Hartford region support advanced healthcare networks, including Yale New Haven Health, which systematically procure single-use diagnostic cartridges to streamline emergency triage and pre-operative clinical workflows.

Maine, New Hampshire, Vermont, and Rhode Island complete the Northeastern landscape, representing stable markets with a mix of academic healthcare hubs and rural community hospital networks. Health systems such as MaineHealth in Portland and Dartmouth Health in New Hampshire utilize single-use CLIA-waived diagnostic cartridges to support primary and urgent care delivery across dispersed rural populations, mitigating the challenges of centralized laboratory transport times.

Healthcare purchasing in the Northeast is evidence-driven and clinically rigorous. With a high concentration of pathology department directors, laboratory medicine specialists, and academic physician executives, hospital procurement committees require detailed analytical validation data, peer-reviewed clinical studies, and compliance with the College of American Pathologists standards before adopting new single-use testing platforms. Diagnostic vendors that provide clinical documentation, high analytical sensitivity, and reliable automated electronic health record data interfaces perform well in this rigorous, quality-focused regional environment.

 

Key Market Players

The competitive landscape of the U.S. Single-Use Point-of-Care Testing Devices Market is characterized by a balance between diversified global diagnostic corporations, established point-of-care medical technology specialists, and innovative microfluidic and molecular technology developers.

Highly relevant players operating in the U.S. single-use point-of-care testing devices industry include:

Abbott Laboratories
QuidelOrtho Corporation
Roche Diagnostics (F. Hoffmann-La Roche Ltd)
Siemens Healthineers AG
Danaher Corporation (Cepheid / Radiometer)
Becton, Dickinson and Company (BD)
bioMérieux SA (BioFire Diagnostics)
Chembio Diagnostics, Inc. (Biosynex Group)
Sekisui Diagnostics, LLC
Meridian Bioscience, Inc. (SD Biosensor)
Nova Biomedical Corporation
Werfen (Instrumentation Laboratory / Accriva Diagnostics)
PTS Diagnostics (Sinocare Inc.)
Cue Health Inc.
Talis Biomedical Corporation / LumiraDx USA Inc.

Abbott Laboratories occupies a preeminent position in the U.S. single-use point-of-care testing market, commanding an extensive installed base across acute care hospitals, urgent care centers, and ambulatory clinics. Abbott’s single-use product portfolio is anchored by its established i-STAT system, which utilizes disposable, single-use microfluidic cartridges to deliver whole-blood critical care chemistry, blood gas, coagulation, and high-sensitivity cardiac troponin results within minutes at the bedside. Furthermore, Abbott’s BinaxNOW rapid lateral flow immunoassay portfolio and ID NOW rapid isothermal molecular testing platform represent high-volume single-use testing products across North American outpatient, retail, and community health networks. Abbott maintains a sustained competitive advantage through long-standing enterprise hospital supply agreements, established medical-surgical distribution relationships, and broad brand equity across clinical environments.

QuidelOrtho Corporation represents a major power in rapid point-of-care diagnostics, formed through the business combination of Quidel Corporation and Ortho Clinical Diagnostics. QuidelOrtho commands significant market share across outpatient and emergency care settings through its Sofia and Sofia 2 fluorescent immunoassay platforms, which utilize single-use lateral flow test cassettes paired with digital optical readers to achieve objective, quantitative diagnostic readouts for respiratory viruses, Group A Strep, and Lyme disease. The company’s QuickVue line of visual lateral flow strips remains an established fixture across physician office laboratories and urgent care clinics, while its Solana and Savanna molecular diagnostic platforms expand its footprint in single-use molecular test cartridges. QuidelOrtho’s extensive distribution channels and established presence in physician offices provide steady recurring consumable revenue.

Roche Diagnostics, the diagnostic division of F. Hoffmann-La Roche Ltd, brings significant medical engineering expertise and analytical scale to the single-use point-of-care testing space. Roche’s point-of-care portfolio includes the cobas b 123 and cobas b 101 systems, alongside its Accu-Chek hospital-grade single-use blood glucose biosensor strip portfolio and the CoaguChek family of single-use PT/INR coagulation test strips. Furthermore, Roche’s cobas Liat system is an established platform in CLIA-waived, single-use point-of-care molecular testing, utilizing a compact disposable cartridge that automates sample purification, micro-PCR amplification, and real-time detection in under twenty minutes. Roche leverages its central laboratory relationships to sell integrated point-of-care testing fleets to large enterprise healthcare systems seeking unified diagnostic workflows.

Siemens Healthineers AG maintains a substantial footprint across the U.S. point-of-care landscape through its clinical laboratory and emergency diagnostic solutions. Siemens Healthineers delivers single-use critical care diagnostics via its epoc Blood Analysis System, which utilizes single-use, room-temperature-stable test cards containing screen-printed biosensor arrays to deliver blood gas, electrolyte, and metabolite results from capillary or arterial blood. In point-of-care urinalysis, the company’s CLINITEK Status+ analyzer paired with Multistix single-use reagent strips remains a standard across American outpatient clinics and emergency departments. Siemens Healthineers emphasizes digital connectivity through its Point of Care Informatics platforms, which integrate single-use testing data into hospital laboratory information systems.

Danaher Corporation participates in the single-use point-of-care testing market through its specialized operating subsidiaries, notably Cepheid and Radiometer. Cepheid is an established market force in rapid molecular diagnostics, driven by its GeneXpert system and patented, single-use self-contained microfluidic cartridges. The GeneXpert cartridge executes automated cell lysis, microfluidic fluid manipulation, and real-time multiplex PCR, providing clinical-laboratory-grade molecular detection for hospital-acquired infections, respiratory pathogens, and sexual health markers. Radiometer complements this presence by delivering critical care point-of-care testing solutions, including single-use blood gas, lactate, and metabolite testing cartridges deployed across emergency departments, operating suites, and neonatal intensive care units throughout the country.

Becton, Dickinson and Company (BD) is an established diagnostic and medical supplies manufacturer with a large presence across U.S. healthcare facilities. In the single-use point-of-care testing domain, BD operates primarily through its BD Veritor Plus System, a digital immunoassay platform utilizing single-use lateral flow cassettes read by a handheld optical instrument to deliver objective, workflow-efficient screening for SARS-CoV-2, Influenza A+B, and Group A Streptococcus. BD’s market position is reinforced by its manufacturing scale, robust nationwide supply chain infrastructure, and clinical relationships across primary care networks, pediatric practices, and occupational health systems.

bioMérieux SA, through its clinical portfolio and BioFire Diagnostics subsidiary, is a recognized authority in syndromic multiplex testing. The BioFire FilmArray system employs single-use, closed-system disposable reagent pouches that integrate sample preparation, reverse transcription, nested multiplex PCR, and melting curve analysis to evaluate up to thirty-four biological targets from a single patient specimen in roughly forty-five minutes. bioMérieux deploys its single-use syndromic testing pouches across hospital emergency departments, pediatric units, and critical care facilities, enabling physicians to diagnose respiratory, gastrointestinal, bloodstream, and central nervous system infections with high diagnostic precision.

Chembio Diagnostics, Inc., operating within the Biosynex Group, is a specialized point-of-care diagnostics developer focused on infectious disease screening. Chembio is known for its proprietary Dual Path Platform (DPP) technology, an advanced lateral flow architecture that separates sample migration from reagent delivery, improving sensitivity and multiplexing capacity compared to conventional lateral flow designs. Chembio supplies single-use test cartridges for the rapid detection of HIV, syphilis, and tropical vector-borne infections to community clinics, public health departments, and hospital emergency screening programs across the United States.

Sekisui Diagnostics, LLC represents an established supplier of rapid point-of-care diagnostic tests to physician office laboratories, urgent care centers, and hospital networks. The company’s single-use portfolio is anchored by its OSOM brand of lateral flow tests, which includes rapid immunoassay kits for Strep A, Influenza, infectious mononucleosis, Trichomonas, and bacterial vaginosis. Sekisui Diagnostics also manufactures the FastPack IP System, a point-of-care immunoassay platform utilizing single-use chemiluminescent reagent packs to deliver quantitative hormone and biomarker results. The company maintains durable distributor relationships with major American healthcare supply distributors, ensuring steady product placement across ambulatory care centers.

Meridian Bioscience, Inc., a division of SD Biosensor, provides diagnostic test kits and biological reagents to outpatient clinics, pediatric practices, and hospital laboratories. Meridian’s single-use point-of-care portfolio features its Curian and ImmunoCard lateral flow immunoassay lines, which provide rapid detection of gastrointestinal pathogens, including Helicobacter pylori, Clostridioides difficile, and Campylobacter. Through its integration with SD Biosensor, Meridian has expanded its single-use diagnostic capabilities, introducing advanced microfluidic and fluorescent lateral flow assays that address emerging infectious diseases and acute respiratory conditions across the U.S. clinical market.

Nova Biomedical Corporation is an American developer and manufacturer of advanced whole-blood point-of-care biosensor analyzers. Nova is recognized for its StatStrip glucose hospital meter systems, which employ single-use electrochemical biosensor test strips engineered with patented multi-well technology that eliminates interference from hematocrit, acetaminophen, uric acid, and ascorbic acid. Nova also manufactures the Stat Sensor line of single-use creatinine and blood urea nitrogen test strips, alongside the Prime Plus critical care blood gas platform utilizing disposable microfluidic cartridges. Nova’s single-use testing products are widely deployed in acute hospital emergency rooms, cardiovascular intensive care units, and outpatient medical imaging suites to ensure rapid patient screening.

Werfen, through its clinical diagnostics divisions including Instrumentation Laboratory and Accriva Diagnostics, is a market leader in specialized critical care and hemostasis testing. The company’s point-of-care offerings feature the GEM Premier family of blood gas and critical care analyzers, which utilize multi-use and single-use cartridge-based solutions, alongside the GEM Hemochron Jr. and VerifyNow platforms, which rely on single-use microfluidic cartridges to deliver Activated Clotting Time and platelet reactivity measurements. Werfen’s single-use hemostasis cartridges are standard fixtures in cardiac catheterization laboratories, cardiovascular surgical suites, and trauma bays, where rapid, single-use coagulation monitoring is required to guide anticoagulant and antiplatelet pharmacotherapy.

PTS Diagnostics, a subsidiary of Sinocare Inc., is a specialized manufacturer of point-of-care biometric and diagnostic testing devices for cardiometabolic disease management. The company’s product line includes the CardioChek family of analyzers, which utilize single-use reflectance photometry test strips to deliver lipid panels and metabolic biomarkers from a single fingerstick drop of capillary blood. PTS Diagnostics also manufactures the A1CNow system, an enclosed, disposable cartridge-based platform that delivers glycated hemoglobin results in five minutes. These products are widely deployed across physician offices, community screening initiatives, retail health clinics, and workplace wellness programs.

Cue Health Inc. has developed a single-use molecular diagnostic testing platform designed for point-of-care and decentralized clinical environments. The Cue Health system comprises a portable, reusable cartridge reader and single-use microfluidic test cartridges that perform automated isothermal nucleic acid amplification. Its single-use cartridges for COVID-19, respiratory viral panels, and sexually transmitted infections deliver clinical-reference-quality molecular results in approximately twenty minutes. Cue Health focuses on user-centric design, integrating automated wireless data transmission into enterprise clinical software networks and telehealth platforms.

Talis Biomedical Corporation / LumiraDx USA Inc. represent innovators in next-generation microfluidic point-of-care testing. The LumiraDx platform features an integrated single-use test strip architecture that combines microfluidic channel dynamics with automated fluorescent optical detection to deliver clinical-laboratory-comparable quantitative results for cardiac markers, D-dimer, CRP, and infectious pathogens from a single drop of whole blood or nasal swab eluate. Talis Biomedical has developed the Talis One molecular diagnostic platform, engineered to deliver rapid, automated single-use molecular testing for urgent care and ambulatory settings. These companies illustrate the continued industry drive toward miniaturized single-use testing platforms that integrate laboratory-grade analytical performance into compact, decentralized workflows.

 

Recent Developments

The U.S. single-use point-of-care testing devices industry has experienced major technological acceleration, regulatory shifts, and commercial restructuring from 2024 through 2026.

A prominent trend across the sector has been the commercialization and clinical adoption of multiplex single-use molecular cartridges capable of differentiating broad syndromic pathogen panels from a single patient swab. Following regulatory approvals by the FDA, major diagnostic vendors launched multi-target CLIA-waived molecular cartridges that test simultaneously for SARS-CoV-2, Influenza A, Influenza B, and RSV with turnaround times under twenty minutes. These platforms, utilizing microfluidic RT-PCR or rapid isothermal amplification chemistries, have been widely adopted across urgent care centers and emergency department triage desks. By providing accurate pathogen differentiation during the initial patient evaluation, these single-use cartridges assist clinicians in prescribing targeted antiviral therapies and reduce inappropriate antibiotic prescriptions across outpatient networks.

The regulatory environment governed by the FDA Center for Devices and Radiological Health has emphasized establishing rigorous Dual 510(k) and CLIA Waiver approval frameworks. Between 2024 and 2026, the FDA streamlined the review of point-of-care diagnostics that combine standard premarket clearance with CLIA-waiver classification, provided that manufacturers integrate fail-safe design controls into single-use cartridges. This policy shift led to several high-sensitivity cardiac troponin, sexually transmitted infection, and whole-blood creatinine single-use cartridges achieving CLIA-waived status. Consequently, outpatient primary care clinics, urgent care centers, and ambulatory surgical suites have expanded their in-house testing menus without requiring certified medical laboratory scientists, altering clinical workflow economics.

Innovation in high-sensitivity cardiac troponin testing has achieved a notable milestone through the commercial introduction of single-use, whole-blood bedside cassettes capable of matching the analytical sensitivity of central laboratory core immunoanalyzers. Medical device manufacturers integrated europium fluorescent nanoparticles and digital microfluidic arrays into disposable cassettes, enabling the detection of troponin at single-digit picogram-per-milliliter concentrations from an uncentrifuged whole-blood fingerstick or venous sample in under fifteen minutes. Clinical trials conducted across American emergency departments demonstrated that these single-use high-sensitivity troponin assays allow physicians to implement rapid one-hour rule-out and rule-in myocardial infarction protocols directly at the bedside, reducing emergency department boarding times and accelerating patient discharges.

The industry has also seen significant manufacturing transitions, with developers moving from manual assembly toward automated roll-to-roll microfluidic embossing, laser welding, and high-speed robotic reagent lyophilization in Class 10,000 cleanrooms. Facing elevated raw material costs and high demand volumes, manufacturers invested heavily in automated production lines capable of producing tens of millions of single-use cartridges annually with low coefficient-of-variation tolerances. Furthermore, chemical engineers developed room-temperature reagent preservation techniques, including advanced matrix-bound lyophilization and sugar-glass vitrification, allowing complex enzymatic and molecular cartridges to maintain eighteen-to-twenty-four-month shelf stability at ambient room temperatures, removing cold-chain shipping and storage costs.

Strategic commercial consolidation and distribution partnerships have reshaped product availability across decentralized care settings. Established healthcare distributors, including McKesson Medical-Surgical, Cardinal Health, and Medline Industries, expanded exclusive distribution agreements with single-use diagnostic device manufacturers. These agreements bundle single-use testing instruments, disposable test cartridges, and digital connectivity software into standardized procurement packages tailored for urgent care networks, retail clinics, and ambulatory surgery center chains. At the same time, diagnostic developers entered into co-marketing partnerships with electronic health record and clinical middleware providers to ensure that single-use testing instruments transmit patient results, lot numbers, and operator credentials directly into hospital information systems via Wi-Fi and Bluetooth LE protocols.

The home health and decentralized chronic disease monitoring sector expanded through the integration of single-use biosensors with digital smartphone reader interfaces. Between late 2024 and 2026, several companies commercialized over-the-counter and prescription single-use testing kits that utilize smartphone optical cameras or near-field communication chips to read, analyze, and report diagnostic results from disposable test strips. These platforms span single-use urine microalbumin screening, fertility monitoring, and infectious disease home testing. The integration of smartphone connectivity allows test results to be uploaded to telehealth portals, enabling remote patient consultations and supporting the expansion of home hospital care models across the United States.

 

Conclusion

The U.S. Single-Use Point-of-Care Testing Devices Market is positioned to expand from USD 18.06 billion in 2026 to approximately USD 29.84 billion by 2032, supported by a steady 8.73% CAGR from 2027 to 2032. Historical market development from USD 14.18 billion in 2023, USD 15.35 billion in 2024, and USD 16.64 billion in 2025 demonstrates the continuous operational utilization and commercial resilience of single-use diagnostic consumables across diverse healthcare economic cycles.

The underlying market thesis is supported by structural shifts across the American healthcare landscape. Clinical demand for immediate therapeutic turnaround times across crowded emergency departments and intensive care suites makes decentralized point-of-care testing a operational necessity. The persisting deficit of certified medical laboratory professionals across hospital networks prevents centralized laboratories from meeting STAT testing requirements, compelling health systems to deploy fool-proof, CLIA-waived single-use cartridges to bedside nursing and clinical staff. Furthermore, the decentralization of care delivery toward thousands of urgent care centers, retail health clinics, and ambulatory surgical centers creates durable, volume-driven demand for self-contained, disposable diagnostic platforms.

Technological advancements have expanded single-use diagnostics from simple qualitative colorimetric strips to microfluidic laboratories-on-a-chip. Lateral flow cassettes and electrochemical biosensors will maintain their high-volume market presence across routine metabolic and cardiac monitoring, while rapid molecular diagnostic cartridges represent the fastest-expanding product category through 2032. The development of ambient-temperature reagent lyophilization, automated cleanroom microfluidic manufacturing, and high-sensitivity digital immunoassays enables single-use consumables to deliver reference-laboratory-grade diagnostic accuracy within minutes from capillary whole blood, swabs, or non-invasive biofluids.

Geographically, the South will maintain revenue leadership through 2032, supported by large population concentrations, high cardiometabolic disease prevalence, and expanding urgent care and hospital networks across Texas and Florida. The West will maintain the fastest technological adoption rate, driven by California’s innovative healthcare delivery models, integrated health maintenance organizations, and early clinical deployment of digital health technologies. The Midwest will continue to supply steady, volume-based demand across regional hospital systems, academic institutions, and rural critical access networks, while the Northeast remains a center of evidence-based clinical testing, utilizing advanced microfluidic and molecular cartridges across its academic medical centers.

For medical device manufacturers, institutional healthcare buyers, and diagnostic distribution networks, competitive success through 2032 will depend on delivering integrated diagnostic solutions. High analytical sensitivity alone is insufficient to maintain market leadership. Successful diagnostic vendors will pair room-temperature-stable, single-use microfluidic cartridges with simple user interfaces, broad CLIA-waived testing menus, automated EHR software interoperability, and dependable supply chain logistics. Companies that master this integrated, single-use consumable model will secure lasting recurring revenue and define the standard of care across decentralized clinical testing throughout the United States.